C
Carol A. Pollock
Researcher at Kolling Institute of Medical Research
Publications - 384
Citations - 18773
Carol A. Pollock is an academic researcher from Kolling Institute of Medical Research. The author has contributed to research in topics: Kidney disease & Diabetes mellitus. The author has an hindex of 63, co-authored 350 publications receiving 14579 citations. Previous affiliations of Carol A. Pollock include University of Sydney & Amgen.
Papers
More filters
Journal ArticleDOI
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic,Vlado Perkovic,Meg Jardine,Meg Jardine,Bruce Neal,Bruce Neal,Bruce Neal,Severine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,David M. Charytan,Robert Edwards,Rajiv Agarwal,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Gary Meininger,Barry M. Brenner,Kenneth W. Mahaffey +30 more
TL;DR: In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years.
Journal ArticleDOI
A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis
Bruce A. Cooper,Pauline Branley,Liliana Bulfone,John F. Collins,Jonathan C. Craig,Margaret B. Fraenkel,Anthony Harris,David W. Johnson,Joan Kesselhut,Jing Jing Li,Grant Luxton,Andrew Pilmore,David J. Tiller,David Harris,Carol A. Pollock +14 more
TL;DR: In this article, the authors examined whether the timing of the initiation of maintenance dialysis influenced survival among patients with chronic kidney disease and found no significant difference between the groups in the frequency of adverse events, infections, or complications of dialysis.
Journal ArticleDOI
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Adeera Levin,Marcello Tonelli,Joseph V. Bonventre,Josef Coresh,Jo Ann Donner,Agnes B. Fogo,Caroline S. Fox,Ron T. Gansevoort,Hiddo J.L. Heerspink,Meg Jardine,Bertram L. Kasiske,Anna Köttgen,Matthias Kretzler,Andrew S. Levey,Valerie A. Luyckx,Ravindra L. Mehta,Orson W. Moe,Gregorio T. Obrador,Neesh Pannu,Chirag R. Parikh,Vlado Perkovic,Carol A. Pollock,Peter Stenvinkel,Katherine R. Tuttle,David C. Wheeler,Kai-Uwe Eckardt +25 more
TL;DR: An action plan and performance framework based on ten themes to strengthen CKD surveillance, tackle major risk factors for CKD, and enhance understanding of the genetic causes of CKD is presented.
Journal ArticleDOI
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Iain C. Macdougall,Andreas J. Bircher,Kai-Uwe Eckardt,Gregorio T. Obrador,Carol A. Pollock,Carol A. Pollock,Peter Stenvinkel,Dorine W. Swinkels,Christoph Wanner,Günter Weiss,Glenn M. Chertow,John W. Adamson,Tadao Akizawa,Stefan D. Anker,Michael Auerbach,Peter Bárány,Anatole Besarab,Sunil Bhandari,Ioav Cabantchik,Alan J. Collins,Daniel W. Coyne,Angel L.M. de Francisco,Steven Fishbane,Carlo A. J. M. Gaillard,Tomas Ganz,David Goldsmith,Chaim Hershko,Ewa A. Jankowska,Kirsten L. Johansen,Kamyar Kalantar-Zadeh,Philip A. Kalra,Bertram L. Kasiske,Francesco Locatelli,Jolanta Malyszko,Gert Mayer,Lawrence P. McMahon,Ashraf Mikhail,Elizabeta Nemeth,Amy Barton Pai,Patrick S. Parfrey,Roberto Pecoits-Filho,Simon D. Roger,Guy Rostoker,Jacques Rottembourg,Ajay K. Singh,Itzchak Slotki,Bruce Spinowitz,Der Cherng Tarng,Francesca Tentori,Jorge E. Toblli,Yusuke Tsukamoto,Nosratola D. Vaziri,Wolfgang C. Winkelmayer,David C. Wheeler,Elena Zakharova +54 more
TL;DR: An expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.
Journal ArticleDOI
Glucose handling by the kidney.
Amanda Mather,Carol A. Pollock +1 more
TL;DR: The kidney contributes to glucose homeostasis through processes of gluconeogenesis, glucose filtration, glucose reabsorption, and glucose consumption, which can be altered in patients with type-2 diabetes (T2DM), providing potential targets for novel therapies.